Difference between revisions of "Lenograstim (Granocyte)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1991-10-11: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory [[acute myeloid leukemia]]. | *2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory [[acute myeloid leukemia]]. | ||
| Line 17: | Line 19: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 1991]] |
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Latest revision as of 12:18, 11 June 2023
This drug is not available in the United States but is available internationally.
Diseases for which it is used
Note that colony stimulating factors are used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; they are not thought to have inherent anti-cancer activity.
History of changes in EMA indication
- 1991-10-11: EURD
History of changes in PMDA indication
- 2022-06-20: New indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia.
Also known as
- Brand names: Granocyte, Neutrogin